Ceritinib

Ceritinib
Clinical data
Trade names Zykadia
AHFS/Drugs.com Multum Consumer Information
Pregnancy
category
  • US: D (Evidence of risk)
Routes of
administration
Oral
ATC code L01XE28 (WHO)
Legal status
Legal status
Identifiers
Synonyms LDK378
CAS Number 1032900-25-6
PubChem (CID) 57379345
DrugBank DB09063
ChemSpider 29315053
UNII K418KG2GET YesY
KEGG D10551
ChEBI CHEBI:78432
ChEMBL CHEMBL2403108
Chemical and physical data
Formula C28H36ClN5O3S
Molar mass 558.14 g/mol
3D model (Jmol) Interactive image

Ceritinib (trade name Zykadia) is a drug for the treatment of a specific type of lung cancer.[1] It is an anaplastic lymphoma kinase (ALK) inhibitor.[2] It was approved in April 2014 by the Food and Drug Administration for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) following treatment with crizotinib.[1]

References

  1. 1 2 "FDA Approves Ceritinib for ALK-Positive Lung Cancer". Medscape. April 29, 2014.
  2. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA (2014). "Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer". N Engl J Med. 370: 1189–1197. doi:10.1056/NEJMoa1311107. PMID 24670165.


This article is issued from Wikipedia - version of the 8/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.